Related references
Note: Only part of the references are listed.Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations
Natasha Rekhtman et al.
MODERN PATHOLOGY (2018)
Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome
Jules L. Derks et al.
CLINICAL CANCER RESEARCH (2018)
Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Tomohiro Miyoshi et al.
CLINICAL CANCER RESEARCH (2017)
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D
Michele Simbolo et al.
JOURNAL OF PATHOLOGY (2017)
Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).
Young Kwang Chae et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets
Natasha Rekhtman et al.
CLINICAL CANCER RESEARCH (2016)
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
Robert J. Cardnell et al.
PLOS ONE (2016)
Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites
Emily K. Bergsland et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pulmonary Large-Cell Neuroendocrine Carcinoma From Epidemiology to Therapy
Morena Fasano et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer
Anna Karlsson et al.
ONCOTARGET (2015)
Treatment Outcomes of Patients With Different Subtypes of Large Cell Carcinoma of the Lung
Yung-Han Sun et al.
ANNALS OF THORACIC SURGERY (2014)
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
J. S. Ross et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis
Shigeki Umemura et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Molecular profiling of small cell lung cancer in a Japanese cohort
Kazushige Wakuda et al.
LUNG CANCER (2014)
Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung A Multicenter Phase II Study
Seiji Niho et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas?
John M. Varlotto et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer
Felix G. Fernandez et al.
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY (2006)
Neuroendocrine neoplasms of the lung: A prognostic spectrum
H Asamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ, and met in large-cell neuroendocrine carcinoma of the lung
G Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer
RJ Battafarano et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2005)
Share Paper
